US2010222591A1PendingUtilityA1

New Compounds

Assignee: LINDBERG PER LENNARTPriority: May 28, 1993Filed: Sep 1, 2009Published: Sep 2, 2010
Est. expiryMay 28, 2013(expired)· nominal 20-yr term from priority
A61P 29/00A61P 31/04A61P 17/06A61P 1/00A61P 19/06A61P 1/04C07D 401/12A61K 31/44
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The novel optically pure compounds Na + , Mg 2+ , Li + , K + , Ca 2+ and N + (R) 4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.

Claims

exact text as granted — not AI-modified
1 . An optically pure enantiomeric compound comprising a Na + , Mg 2+ , Li + , K + , Ca 2+  or N + (R) 4  salt of (+)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, wherein R is an alkyl with 1-4 carbon atoms. 
   
   
       2 - 34 . (canceled)

Join the waitlist — get patent alerts

Track US2010222591A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.